Cannabis is quite a polarizing topic. For many, it’s a drug to be avoided at all costs, and for others, a resource that’s filled with endless possibilities. For a while now, researchers have been studying a group of unique chemicals produced by cannabis called cannabinoids.
Although there are over 100 of them, most of our knowledge of cannabinoids is centered on cannabidiol (CBD) and THC (delta-9 tetrahydrocannabinol).
THC is psychoactive, and it is responsible for marijuana’s infamous high. CBD isn’t psychoactive, and its biggest draw is its medicinal properties. While both of them have therapeutic effects, CBD can be said to have more potent medicinal properties.
For long, the consensus was that THC was the strongest psychoactive cannabinoid, but the discovery of new cannabinoids using cutting edge spectrometry has put that notion to test. A group of Italian scientists recently discovered THCP (tetrahydrocannabiphorol), a cannabinoid that’s said to be 30 times stronger than THC, as well as cannabidiphorol (CBDP).
THCP is quite similar in structure to THC, with only one minor difference. THC’s molecular structure consists of a five link side chain, while THCP has seven links in its structure. According to cannabis author Jaime Evans, this allows the newly discovered cannabinoid to act with greater effectiveness than THC.
“It’s been reported that it has an immense affinity for binding with CB1 receptors which are primarily found in the brain and body and help regulate anxiety, stress, pain relief, mood, happiness and more,” she says.
The researchers concluded that THCP was 33 times more active than regular THC on CB1 receptors, and 5-10 times more active than regular THC on CB2 receptors.
CB1 and CB2 receptors are part of the endocannabinoid system, a nervous system that regulates functions like sleep and pain. Cannabinoids like THC, CBD, and THCP bind to these receptors, and as THCP binds strongly with the receptors, the effects it creates are a lot stronger.
CBDP also has a longer side chain on seven links, instead of the expected five. However, since regular CBD has poor binding affinity with both the CB1 and CB2 receptors, it’s unlikely a longer side chain will make CBDP bind more effectively. Due to this, the research into the cannabinoid’s anti-inflammatory, anti-oxidant and antiepileptic activity will carry on, but it won’t be a priority.
However, nothing is set in concrete in the cannabis sector. It has largely been dependent on technology to move forward, and future research may find uses for CBDP that we aren’t currently aware of.
Analysts believe that the discovery of THCP and CBDP doesn’t come as news to CBD sector companies like HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) who believe that what is currently known about the hemp plant is just a tip of the iceberg.
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.